
AstraZeneca PLC (AZN) Earnings Dates & Reports
AstraZeneca PLC (AZN) Most Recent Earnings
Report Date
Period EndingQ3 2025
Est. EPS$1.14
Actual EPS$1.19
EarningsBeat
AstraZeneca PLC (AZN) Earnings
View the latest AstraZeneca PLC (AZN) earnings report, listen to the earnings call, and analyze historical earnings performance with AI-powered insights.
Start investing in AstraZeneca PLC (AZN)
Order type
Buy in
Order amount
Est. shares
0 shares
AstraZeneca PLC (AZN) Earnings per Share (EPS) History
Signup for full accessBrowse free
AstraZeneca PLC (AZN) Latest Earnings
The value each AZN share was expected to gain vs. the value each share gained.
AstraZeneca PLC (AZN) reported its most recent earnings on for Q3 2025, posting earnings per share (EPS) of $1.19. This exceeded analysts' expectations of $1.14 by 4.39%, marking a Beat.
For comparison, AstraZeneca PLC reported EPS of $1.04 in the same quarter last year.
The company is expected to announce its next earnings report on , with analysts projecting an EPS of $1.08.
AstraZeneca PLC (AZN) Earnings History
AstraZeneca PLC (AZN) Earnings Related Price Changes
Earnings announcements may impact a stock’s price. This table highlights the AstraZeneca PLC’s price movement by comparing the day-before and day-after prices of recent earnings reports, along with the percentage change.
| Report date | Price 1D before | Price 1D after | Change |
|---|---|---|---|
| — | — | — | |
| — | — | — | |
| — | — | — | |
| — | — | — |
AstraZeneca PLC (AZN) Earnings FAQs
AstraZeneca PLC (AZN) last reported earnings on Nov 6, 2025 for Q3 2025, posting an EPS of $1.19, which Beat the estimate of $1.14 by 4.39%.
For Q3 2025, AstraZeneca PLC (AZN) reported an EPS of $1.19, exceeding analysts' estimate of $1.14 by 4.39%.
For Q3 2025, AstraZeneca PLC (AZN) Beat expectations with an actual EPS of $1.19 vs. an estimated EPS of $1.14.
Following the last earnings report on Nov 6, 2025, AstraZeneca PLC (AZN)'s stock price moved — from — to —.
The next AstraZeneca PLC (AZN) earnings call is scheduled for Feb. 10, 2026, where executives will discuss financial results and outlook.